A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
Latest Information Update: 22 Nov 2024
Price :
$35 *
At a glance
- Drugs Pegunigalsidase alfa (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Pharmacodynamics
- Acronyms MODERN
- Sponsors Chiesi Farmaceutici SpA
- 01 Nov 2024 New trial record